Response to the complete hepatitis B vaccine regimen in infants under 12 months of age: a case series  by Miralha, Alexandre Lopes et al.
b r a z j i n f e c t d i s . 2 0 1 3;1 7(1):82–85
The Brazilian Journal of
INFECTIOUS  DISEASES
www. elsev ier .com/ locate /b j id
Brief communication
Response  to the complete  hepatitis  B vaccine  regimen  in
infants under  12  months  of  age:  a case  series
Alexandre Lopes Miralhaa,b,∗, Adriana Malheiroc,d, Angélica Espinosa Mirandac,e,
George Williams Rutherfordf, Maria das Grac¸as Costa Alecrimc,g
a Universidade do Estado do Amazonas, Amazonas Foundation of Tropical Medicine, Manaus, AM, Brazil
b Department of Maternal and Child Healthcare, Universidade Federal do Amazonas; and the Discipline of Pediatric Healthcare I,
Universidade Nilton Lins, Manaus, AM, Brazil
c Postgraduate Program in Tropical Medicine, Universidade do Estado do Amazonas; and the Amazonas Foundation of Tropical Medicine,
Manaus, AM, Brazil
d Amazonas Foundation of Hematology and Hemotherapy, Universidade Federal do Amazonas, Manaus, AM,  Brazil
e Department of Social Medicine, Universidade Federal do Espírito Santo, Vitória, ES, Brazil
f Department of Epidemiology & Biostatistics, University of California, San Francisco, United States
g Undergraduate Medical Course, Universidade Nilton Lins, Manaus, AM,  Brazil
a  r  t  i  c  l  e  i  n  f  o
Article history:
Received 7 June 2012
Accepted  27 July 2012
Available  online 29 December 2012
Keywords:
Newborn infant
Prematurity
Hepatitis  B vaccine
Seroconversion
a  b  s  t  r  a  c  t
Objectives: Describing rates of seroconversion and its associated factors in a series of Brazil-
ian  infants following the ﬁnal dose of the vaccine at 6 months of age.
Methods:  Peripheral blood samples were collected after the third dose of the vaccine for the
detection  of anti-hepatitis B surface antibodies among infants of 7–12 months of age. We
measured  the association between seroconversion and birthweight, gestational age, time
since  administration of the vaccine in the maternity hospital and whether or not testing for
hepatitis  B surface antigen had been performed during pregnancy.
Results:  We examined 40 infants. The mean birthweight was  2787 g (standard devia-
tion  = 853 g) and mean gestational age was 37.5 (standard deviation = 3.08) weeks. The
proportion  that seroconverted was non-signiﬁcantly higher in infants who weighed ≥2000 g
at birth (96.7%) than in those with birthweights <2000 g (80%, p = 0.149). There was no dif-
ference  between the infants who were born at <37 weeks of gestational age and those born
at  ≥37 weeks (p < 0.178) neither between seroconversion and the time of application of the
ﬁrst  dose of the vaccine after delivery (p = 0.202).Conclusion: The proportion of infants who seroconverted was similar to that found in other
Brazilian  studies. There were no differences in the proportion seroconverting by age at ﬁrst
immunization.
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ne of the characteristics of hepatitis B virus (HBV) infection is
 greater risk for chronic infection when the virus is acquired
arly  in life,1,2 ranging from 80% to 90% for those acquired in
he  neonatal period and from 30% to 50% for those acquired
uring  later childhood.2,3 The risk of progression to chronic
epatitis decreases to 5–10% when the infection is acquired in
dolescence or adulthood.1,3
Although distribution of HBV is global, its endemic proﬁle
iffers  substantially.1 In Brazil, around 1% of the population
re  chronic carriers of hepatitis B.4,5 The Amazon region has
een  classiﬁed as an area of high endemicity, with a preva-
ence  of HBsAg that reaches as high as 8%.5 In the state of
mazonas, the prevalence of HBsAg positivity in pregnant
omen  varies from 4% to 8% in the regions of the Juruá and
urus  rivers.6
Vaccination of full-term newborn infants has been shown
o  achieve seroconversion rates of over 95% after completion
f  the three-dose vaccination regimen when the ﬁrst dose is
dministered  on the ﬁrst day of life (preferably in the ﬁrst
2  h), irrespective of dose and/or the strain used in the pro-
uction  of the vaccine.3,7,8 Questions remain with respect to
eroconversion in preterm newborn infants who complete the
ull  vaccine regimen, even when immunization is initiated in
he ﬁrst few days of life and particularly in those weighing
2000 g at birth. Studies published after 1991 report a varia-
ion  in the proportion of preterm infants weighing <2000 g at
irth  who  seroconvert, which range from 55% to 100%.8–11 HBV
accination at birth was  ofﬁcially instituted in the childhood
mmunization schedule in Brazil in 1997, coverage being based
n  the fact that transmission in early infancy occurs most fre-
uently  in populations in which HBV infection is highly or
oderately  endemic.12
The objective of the present study was  to describe immuno-
ogical  response to the complete 3-dose hepatitis B vaccine
egimen and to assess factors associated with seroconversion
n  a series of infants up to 12 months of age receiving outpa-
ient  care at a public maternity hospital in Manaus.
aterial  and  methods
his study was  conducted in the city of Manaus, Amazonas,
razil, between July 2009, and May  2010. The sample was
elected  at the outpatient clinic of the Balbina Mestrinho
aternity Hospital, which is considered a referral center for
igh-complexity neonatal and obstetric care for residents of
mazonas.  The study was  approved by the Internal Review
oard  of the Amazonas Foundation of Tropical Medicine under
pproval  3573-08/FMT-AM.
Infants  who participating in the study were selected from
he  medical records of outpatients who  fulﬁlled the following
nclusion  criteria: child of an HBsAg-negative mother (when
erological status was  known) or of unknown HBsAg status;
etween  7 and 12 months of age irrespective of gestational
ge  and/or birthweight; and had completed the entire vaccine
egimen  (Buthang® recombinant DNA vaccine) prior to their
-month  birthday, as registered in the child’s healthcare card 1 3;1  7(1):82–85  83
in  accordance with the Ministry of Health’s National Immu-
nization  Program.12
After the mothers or guardians had signed the informed
consent form, a questionnaire was  completed with data on
their  pregnancy, delivery and immediate postpartum, as well
as  their medical history prior to the time of consultation. Ges-
tational  age at birth was recorded from the mother’s hospital
chart  and the child’s healthcare card, using the curve estab-
lished  by Alexander et al.13 to determine the adequacy of
birthweight for gestational age. After the interview, a 1,5 mL
sample  of peripheral blood was  taken from the infant and sent
to  the Amazonas Foundation of Hematology and Hemother-
apy  for serological testing to detect antibodies against the
hepatitis  B surface antigen (HBsAb) using ELISA (Abbott Murex,
UK).  We  deﬁned seroconversion as having an HBsAb titer of
≥10  mIU/mL.
The  database was  analyzed using the SPSS statistical soft-
ware  program,  version 17.0. A descriptive statistical analysis
was  performed, and possible associations between low birth-
weight  and the independent variables were tested using the
Fisher  exact test, with p-values < 0.05 being considered statis-
tically  signiﬁcant.
Results
A total of 40 infants between 7 and 12 months of age seen at the
outpatient  department during the study period were  enrolled.
Parents  of 13 infants declined to participate. Mean gestational
age  was 37.5 (standard deviation [SD] = 3.08) weeks. Mean
birthweight was 2787 (SD = 853) g; 18 (45%) were  male and 22
(55%)  female. Ten (25%) of the infants weighed <2000 g at birth,
while  the remaining 30 (75%) weighed ≥2000 g. Twenty-four
(60%) mothers had been tested prenatally for HBsAg, and all
were  negative
Overall 36 (90%) infants seroconverted. Twenty-eight (97%)
infants  with birthweight ≥2000 g seroconverted compared to
8 (80%) of those weighing <2000 g at birth (p = 0.149) (Table 1).
There  was  no signiﬁcant difference in the proportion sero-
converting between the infants who were born at <37 weeks
of  gestational age and those born at ≥37 weeks (p < 0.178),
Twenty-three (58%) infants received their ﬁrst dose of the vac-
cine  in the maternity hospital (≤48 h of life); 73% of these
weighed ≥2000 g at birth. Of the children who  received the ﬁrst
dose  of the vaccine prior to 24 h of life, only 1 (10%) weighed
<2000 g at birth. There were no differences in the proportion
seroconverting by age at ﬁrst immunization (p = 0.116).
Discussion
This is the ﬁrst study to be carried out in the Amazon region
that  evaluates serological response to hepatitis B vaccine in
which  premature newborn (<37 weeks) and low birthweight
infants were included. We found no signiﬁcant difference
in  seroconversion between those who weighed <2000 g at
birth  and those weighing ≥2000 g following three doses of
® 14the  Buthang vaccine. Chawareewong et al. studied 25 pre-
mature  infants of HBsAg-negative mothers in Thailand and
reported  overall seroconversion rates of around 88% after com-
pletion  of the 3-dose regimen of the recombinant DNA vaccine
84  b r a z j i n f e c t d i s . 2 0 1 3;1 7(1):82–85
Table 1 – Factors associated with seroconversion to HBsAg among infants, Balbina Mestrinho Maternity Hospital, Manaus,
Amazonas.
Variables Anti-HBs
≥10 mUI/mL
Anti-HBs
<10 mUI/mL
p-value*
n % n %
Birthweight
≥2000 g 29 96.7 1 3.3 0.149
<2000 g 8 80.0 2 20.0
Maternal serology during prenatal
care  or at the maternity hospital
HBsAg  performed (tested negative) 22 91.7 8 8.3 0.625
HBsAg not performed 15 93.2 1 6.3
Gestational age
<37  weeks 9 24.3 2 18.2 0.178
≥37 weeks 28 75.7 1 3.4
Infant gender
Male  17 94.4 1 5.6 0.577
Female 20 90.9  2 9.1
Administration of the ﬁrst dose of the vaccine
<12 h after birth 1 100.0 0 0 0.116
12–23 h after birth 21 95.5 1 4.5
24–47 h after birth 0 0 0 0
≥48 h after birth 15 88.2 2 11.8∗ p < 0.05 (Fisher exact test).
when the ﬁrst dose was  applied up to the tenth day of life.
Our  ﬁnding of an 80% seroconversion rate in infants weighing
<2000  g at birth was  similar to that found in Thailand (88%).
Of the studies conducted in Brazil that evaluated serocon-
version following the complete vaccination regimen against
hepatitis  B and that also included the sample premature
infants (<37 weeks) and low birthweight infants, two are note-
worthy.  Freitas da Motta evaluated 110 newborn infants (57
full  term infants and 53 premature infants) and reported
that  77% of the premature infants with birthweight <1800 g
seroconverted  after use of the Engerix B® vaccine (Smith
Kline  Beecham).9 Sadeck reported that 75% of infants weigh-
ing  <1500 g at birth seroconverted following use of the
Recombivax® vaccine (Merck Sharp & Dohme).10 The two stud-
ies  were  conducted in the southeast of Brazil with vaccines
produced from the same strain of fungi (Saccharomyces cere-
visiae);  however, the doses were different (RecombivaxHB®:
5  g/dose of 0.5 mL;  Engerix B®: 10 g/dose of 0.5 mL).
Golebiowska reported that 98.4% of vaccinated preterm
infants had levels >10 mIU/mL following a 4-dose vaccine reg-
imen  (at 0, 1, 2 and 12 months) and that administration of the
vaccine  after the ﬁrst day of life was  correlated with low anti-
HBs  levels when birthweight was  <2000 g compared to infants
with  birthweight ≥2000 g.15 In our study, there were no dif-
ferences  between the time of application and seroconversion
after completion of the vaccine regimen, since the majority
of  the infants who  responded to the vaccine weighed ≥2000 g.
The Ministry of Health routinely recommends application of
the  ﬁrst dose of the vaccine in the maternity hospital and
preferably within the ﬁrst 12 h following delivery, irrespective
of  whether the mother’s serological status is known or not.12
Our study was  primarily limited by its small sample size.
Additionally we  were unable to recruit many  infants withbirthweight <2000 g. It is difﬁcult on a outpatient basis in view
of  the high rate of child mortality in the city of Manaus, which
was  around 15.93 per 1000 liveborn infants for the year 2008
(unpublished data, State Health Department, Manaus), and
because  of the loss-to-follow-up that occurred during out-
patient  evaluation of child development, which resulted in
difﬁculties  in selecting infants between 7 and 12 months of
age  with a low birthweight.
Further  studies aimed at identifying factors that could
determine the absence of seroconversion or a delay in achiev-
ing  seroconversion following completion of an anti-hepatitis
B  vaccine regimen, particularly in infants whose birthweight
was  <2000 g. These studies may  provide information on the
best  way  to ensure the immunization of children against HBV
infection  in the Amazon region, which could lead to control of
transmission  of the disease. Currently, the state of Amazonas
struggles to increase immunization coverage, with the goal of
achieving  95% vaccine coverage for all age groups, particularly
for  those under 12 months of age.
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